David Bailey, an analyst from Morgan Stanley, maintained the Buy rating on Resmed (RMD – Research Report). The associated price target remains the same with $280.00.
David Bailey has given his Buy rating due to a combination of factors including Resmed’s strong financial performance and growth prospects. The company’s revenue is projected to grow by 8% year-over-year, with an expected improvement in incremental margins and operating leverage leading to a 9.5% increase in earnings per share.
Additionally, Bailey notes that Resmed’s ability to offset potential tariff impacts through low single-digit price adjustments across its product range is a positive indicator. The focus on new patient starts, margin expectations, and strategic capital deployment further supports the optimistic outlook for Resmed’s stock.
In another report released on April 10, Robert W. Baird also maintained a Buy rating on the stock with a $252.00 price target.